PROJECT
Pre-clinical evaluation of homeopathy drugs for treating drug sensitive and resistant isolates of Mycobacterium tuberculosis – Stage I & Stage II
July, 2025 - June, 2028
Objectives:
To determine the immunomodulatory role of homeopathy drugs in Mycobacterium tuberculosis (Mtb) infected cell lines; To determine the safety of the homeopathy drugs in cell lines of different origin; To determine the anti-TB nature of the homeopathic drugs against laboratory strains of Mtb
Study Overview:
Integrating homeopathic formulations into the exploration of host-directed therapy, specifically targeting immunomodulation in tuberculosis is the uniqueness of this proposed study. It uniquely investigates the potential of these agents to influence PTLD-related immune sequelae while simultaneously evaluating their adjunct anti-TB effects. Such an approach may open new avenues for low-toxicity, immune-based interventions in MDR-TB management.
Study Approach:
This is an invitro and invivo based laboratory study
Expected Public Health Impact:
The study will be able to bring out the preclinical data in respect to Homoepathy drugs for TB
Principal Investigator
